PERFETTI, RICCARDO et al
"186-OR: Safety and Tolerability of the Next Generation Aldose Reductase Inhibitor (ARI) AT-001 Supports Initiation of the Pivotal Trial in Diabetic Cardiomyopathy (DbCM)." Diabetes
69.Supplement 1
(2020):
186-OR.
Web. 11 April. 2021.
